Arrowhead Pharmaceuticals · 14 hours ago
Summer Intern, Biochemistry (Cell-Based Assay Development)
Arrowhead Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative drugs that treat intractable diseases through RNA interference. The Summer Intern in Biochemistry will support discovery research by contributing to the development and execution of cell-based assays for antibody screening, gaining hands-on laboratory experience and working closely with scientists.
BiotechnologyHealth CareNanotechnologyPharmaceutical
Responsibilities
Maintain primary and established cell lines to support ongoing research activities
Perform molecular biology tasks, including plasmid preparation and construction
Generate experimental data using techniques such as multicolor flow cytometry and ELISA
Isolate proteins, DNA, and RNA from cell cultures and conduct analyses using qPCR, SDS-PAGE, and Western blot
Analyze, interpret, and organize experimental data with strong attention to detail
Assist with routine instrument maintenance, inventory management, and general laboratory upkeeping
Maintain accurate experimental records and contribute to reports or documentation as needed
Comply with EHS guidelines, complete required safety training, and follow SOPs to ensure data integrity and regulatory compliance
Qualification
Required
Bachelor's degree (completed or in progress) in Biological Sciences or a related field
Completion of relevant coursework in biology or life sciences
Familiarity with routine molecular and cellular biology techniques
Hands-on experience with ELISA and flow cytometry
Familiarity with cell-based assay development or antibody screening
Proficiency in Microsoft Office applications
Strong curiosity and motivation to learn new laboratory techniques
Benefits
Competitive salaries
Excellent benefit package
Company
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Funding
Current Stage
Public CompanyTotal Funding
$2.45BKey Investors
Sarepta TherapeuticsSixth StreetSilence Therapeutics
2026-01-07Post Ipo Equity· $200M
2026-01-07Post Ipo Debt· $625M
2024-11-26Post Ipo Equity· $325M
Leadership Team
Christopher Anzalone
President and Chief Executive Officer
Recent News
2026-01-14
Company data provided by crunchbase